TFP5 prevents 1-methyl-4-phenyl pyridine ion-induced neurotoxicity in mouse cortical neurons

Zhang,Qi‑Shan; Liao,Yuan‑Gao; Ji,Zhong; Gu,Yong; Jiang,Hai‑Shan; Xie,Zuo‑Shan; Pan,Su‑Yue; Hu,Ya‑Fang

doi:10.3892/etm.2016.3658

TFP5 prevents 1-methyl-4-phenyl pyridine ion-induced neurotoxicity in mouse cortical neurons

Authors:
- Qi‑Shan Zhang
- Yuan‑Gao Liao
- Zhong Ji
- Yong Gu
- Hai‑Shan Jiang
- Zuo‑Shan Xie
- Su‑Yue Pan
- Ya‑Fang Hu
View Affiliations

Affiliations: Department of Neurology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China
Published online on: September 5, 2016 https://doi.org/10.3892/etm.2016.3658
Pages: 2594-2598
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the protective effect of a modified p5 peptide, TFP5, on 1-methyl-4-phenyl pyridine ion (MPP+)-induced neurotoxicity in cortical neurons and explore the therapeutic effect of TFP5 on Parkinson's disease (PD). MPP+ was applied to a primary culture of mouse cortical neurons to establish the cell model of PD. Neurons were divided into four groups: Control, model (MPP+), scrambled peptide (Scb) (Scb + MPP+) and TFP5 (TFP5 + MPP+) groups. Pretreatment with Scb or TFP5 was applied to the latter two groups, respectively, for 3 h, while phosphate‑buffered saline was applied to the control and model groups. MPP+ was then applied to all groups, with the exception of the control group, and neurons were cultured for an additional 24 h. Neuron viability was evaluated using a Cell Counting kit‑8 (CCK8) assay. To explore the mechanism underlying the protective effects of TFP5, the expression levels of p35, p25 and phosphorylated myocyte enhancer factor 2 (p‑MEF2D) were determined by western blotting. Fluorescence microscopy showed that TFP5 was able to pass through cell membranes and distribute around the nucleus. CCK8 assay showed that neuronal apoptosis was dependent on MPP+ concentration and exposure time. Cell viability decreased significantly in the model group compared with the control group (55±7 vs. 100±0%; P<0.01), and increased significantly in the TFP5 group compared with the model group (98±2 vs. 55±5%; P<0.01) and Scb group (98±2 vs. 54±4%; P<0.01). Scb exhibited no protective effect. Western blotting results showed that MPP+ induced p25 and p‑MEF2D expression, TFP5 and Scb did not affect MPP+‑induced p25 expression, but TFP5 reduced MPP+‑induced p‑MEF2D expression. In summary, TFP5 protects against MPP+‑induced neurotoxicity in mouse cortical neurons, possibly through inhibiting the MPP+‑induced formation and elevated kinase activity of a cyclin‑dependent kinase 5/p25 complex.

View Figures

View References

1	Rascol O: Drugs and drug delivery in PD: Optimizing control of symptoms with pramipexole prolonged-release. Eur J Neurol. 18 Suppl 1:S3–S10. 2011. View Article : Google Scholar
2	Salat D and Tolosa E: Levodopa in the treatment of Parkinson's disease: Current status and new developments. J Parkinsons Dis. 3:255–269. 2013.PubMed/NCBI
3	Wood-Kaczmar A, Gandhi S and Wood NW: Understanding the molecular causes of Parkinson's disease. Trends Mol Med. 12:521–528. 2006. View Article : Google Scholar : PubMed/NCBI
4	Su SC and Tsai LH: Cyclin-dependent kinases in brain development and disease. Annu Rev Cell Dev Biol. 27:465–491. 2011. View Article : Google Scholar : PubMed/NCBI
5	Lee MS, Kwon YT, Li M, Peng J, Friedlander RM and Tsai LH: Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature. 405:360–364. 2000. View Article : Google Scholar : PubMed/NCBI
6	Alvira D, Ferrer I, Gutierrez-Cuesta J, Garcia-Castro B, Pallàs M and Camins A: Activation of the calpain/cdk5/p25 pathway in the girus cinguli in Parkinson's disease. Parkinsonism Relat Disord. 14:309–313. 2008. View Article : Google Scholar : PubMed/NCBI
7	Hattori N and Mizuno Y: Pathogenetic mechanisms of parkin in Parkinson's disease. Lancet. 364:722–724. 2004. View Article : Google Scholar : PubMed/NCBI
8	Smith PD, Crocker SJ, Jackson-Lewis V, Jordan-Sciutto KL, Hayley S, Mount MP, O'Hare MJ, Callaghan S, Slack RS, Przedborski S, et al: Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci USA. 100:13650–16655. 2003. View Article : Google Scholar : PubMed/NCBI
9	Wong AS, Lee RH, Cheung AY, Yeung PK, Chung SK, Cheung ZH and Ip NY: Cdk5-mediated phosphorylation of endophilin B1 is required for induced autophagy in models of Parkinson's disease. Nat Cell Biol. 13:568–579. 2011. View Article : Google Scholar : PubMed/NCBI
10	Avraham E, Rott R, Liani E, Szargel R and Engelender S: Phosphorylation of Parkin by the cyclin-dependent kinase 5 at the linker region modulates its ubiquitin-ligase activity and aggregation. J Biol Chem. 282:12842–12850. 2007. View Article : Google Scholar : PubMed/NCBI
11	Smith PD, Mount MP, Shree R, Callaghan S, Slack RS, Anisman H, Vincent I, Wang X, Mao Z and Park DS: Calpain-regulated p35/cdk5 plays a central role in dopaminergic neuron death through modulation of the transcription factor myocyte enhancer factor 2. J Neurosci. 26:440–447. 2006. View Article : Google Scholar : PubMed/NCBI
12	Camins A, Verdaguer E, Folch J, Canudas AM and Pallàs M: The role of CDK5/P25 formation/inhibition in neurodegeneration. Drug News Perspect. 19:453–460. 2006. View Article : Google Scholar : PubMed/NCBI
13	Zhang L, Liu W, Szumlinski KK and Lew J: p10, the N-terminal domain of p35, protects against CDK5/p25-induced neurotoxicity. Proc Natl Acad Sci USA. 109:20041–20046. 2012. View Article : Google Scholar : PubMed/NCBI
14	Rosales JL and Lee KY: Extraneuronal roles of cyclin-dependent kinase 5. Bioessays. 28:1023–1034. 2006. View Article : Google Scholar : PubMed/NCBI
15	Lopes JP and Agostinho P: Cdk5: Multitasking between physiological and pathological conditions. Prog Neurobiol. 94:49–63. 2011. View Article : Google Scholar : PubMed/NCBI
16	Piedrahita D, Hernández I, López-Tobón A, Fedorov D, Obara B, Manjunath BS, Boudreau RL, Davidson B, Laferla F, Gallego-Gómez JC, et al: Silencing of CDK5 reduces neurofibrillary tangles in transgenic alzheimer's mice. J Neurosci. 30:13966–13976. 2010. View Article : Google Scholar : PubMed/NCBI
17	Shukla V, Zheng YL, Mishra SK, Amin ND, Steiner J, Grant P, Kesavapany S and Pant HC: A truncated peptide from p35, a Cdk5 activator, prevents Alzheimer's disease phenotypes in model mice. FASEB J. 27:174–186. 2013. View Article : Google Scholar : PubMed/NCBI
18	Gong CX and Iqbal K: Hyperphosphorylation of microtubule-associated protein tau: A promising therapeutic target for Alzheimer disease. Curr Med Chem. 15:2321–2328. 2008. View Article : Google Scholar : PubMed/NCBI
19	Xu SY, Wu YM, Ji Z, Gao XY and Pan SY: A modified technique for culturing primary fetal rat cortical neurons. J Biomed Biotechnol. 2012:8039302012. View Article : Google Scholar : PubMed/NCBI
20	Shukla V, Skuntz S and Pant HC: Deregulated Cdk5 activity is involved in inducing Alzheimer's disease. Arch Med Res. 43:655–662. 2012. View Article : Google Scholar : PubMed/NCBI
21	Wen Z, Shu Y, Gao C, Wang X, Qi G, Zhang P, Li M, Shi J and Tian B: CDK5-mediated phosphorylation and autophagy of RKIP regulate neuronal death in Parkinson's disease. Neurobiol Aging. 35:2870–2880. 2014. View Article : Google Scholar : PubMed/NCBI
22	Zheng YL, Amin ND, Hu YF, Rudrabhatla P, Shukla V, Kanungo J, Kesavapany S, Grant P, Albers W and Pant HC: A 24-residue peptide (p5), derived from p35, the Cdk5 neuronal activator, specifically inhibits Cdk5-p25 hyperactivity and tau hyperphosphorylation. J Biol Chem. 285:34202–34212. 2010. View Article : Google Scholar : PubMed/NCBI
23	Namura I, Douillet P, Sun CJ, Pert A, Cohen RM and Chiueh CC: MPP⁺ (1-methyl-4-phenylpyridine) is a neurotoxin to dopamine-, norepinephrine- and serotonin-containing neurons. Eur J Pharmacol. 136:31–37. 1987. View Article : Google Scholar : PubMed/NCBI
24	Xie HR, Hu LS and Li GY: SH-SY5Y human neuroblastoma cell line: In vitro cell model of dopaminergic neurons in Parkinson's disease. Chin Med J (Engl). 123:1086–1092. 2010.PubMed/NCBI
25	Binukumar BK, Zheng YL, Shukla V, Amin ND, Grant P and Pant HC: TFP5, a peptide derived from p35, a Cdk5 neuronal activator, rescues cortical neurons from glucose toxicity. J Alzheimers Dis. 39:899–909. 2014.PubMed/NCBI